This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Deciphera Pharmaceuticals LLC (small-molecule cancer therapies) raised $52mm in its Series C round to lead investors Redmile Group, Viking Global Investors, and Sphera Global Healthcare Fund, which were joined by existing investors including New Leaf Venture Partners. Funds will support ongoing development of DCC2618 (in Phase I for gastrointestinal stromal tumors, aggressive systemic mastocytosis, and malignant gliomas) and DCC3014 (Phase I for advanced malignancies). Deciphera last raised funds through a Series B round that began at $75mm in 2015 and closed at over $90mm last year.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?